Aegerion Pharmaceuticals: Amryt buys Aegerion via bankruptcy, adding sales to support R&D
Amryt Pharma has completed the acquisition of Aegerion Pharmaceuticals. The deal, which comes after Aegerion filed for Chapter 11 bankruptcy, gives Amryt near-full control of two commercial drugs.
Read full article »
CEO
Aegerion is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of severe and rare diseases.
Read more